Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 AMG 910 in CLDN18.2-positive gastric/GEJ adenocarcinoma
NL-OMON55179Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gresonitamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 2 more. Started Jun 2021; status: completed.
02
Drugs
gresonitamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON55179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55179.